This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ABC-02 was a completed phase 3 randomized parallel-group treatment trial evaluating cisplatin plus gemcitabine versus gemcitabine in patients with unresectable locally advanced or metastatic biliary tract tumors.
| Feature | ABC-02 |
|---|---|
| Condition | Extrahepatic Bile Duct Cancer; Gallbladder Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | University College, London |
2. Clinical Question
Population
Patients with unresectable locally advanced or metastatic cholangiocarcinoma or other biliary tract tumors.
Intervention
Cisplatin and gemcitabine hydrochloride.
Comparator
Gemcitabine-based comparator treatment.
Primary question
Does the randomized treatment comparison improve overall survival?
3. Trial Design
324 patients
2 arms
Cisplatin / Gemcitabine
Up to 5 years
4. Primary Endpoint
| Endpoint | Definition |
|---|---|
| Overall Survival | From date of randomisation till date of death or last date of follow-up (up to 5 years) |
5. Statistical Methodology
The registry identifies overall survival as the primary endpoint. Overall survival is a time-to-event endpoint, meaning the analysis generally focuses on the time from randomization until death while accounting for patients whose follow-up ends before an event occurs.
Time-to-event analysis
Overall survival endpoints are commonly summarized using Kaplan-Meier estimation, which describes the estimated probability of remaining event-free over time while incorporating censored observations.
S(t) = probability of survival beyond time t
The Kaplan-Meier estimator updates survival estimates at observed event times using the number of patients at risk and the number of events.
Comparing randomized groups
Randomized survival comparisons are commonly performed using methods such as the log-rank test and Cox proportional-hazards models. These approaches evaluate whether the observed survival experience differs between treatment groups while accounting for follow-up duration.
6. Planned Analysis
The registry states that overall survival was measured from randomisation until death or the last date of follow-up, up to 5 years. Results have not been posted on ClinicalTrials.gov.
For an endpoint of this type, a typical statistical analysis would estimate survival curves, compare treatment groups using a time-to-event method, and summarize relative treatment effects using a hazard ratio with confidence intervals.
7. Statistical Methods Explained
Why is overall survival a time-to-event endpoint?
Overall survival measures not only whether an event occurred, but also when it occurred. Patients followed for different lengths of time contribute different amounts of information.
Why are censored observations important?
If a patient has not experienced the event by the end of available follow-up, their information is incomplete but still contributes to the survival analysis up to the censoring point.
What does randomization contribute statistically?
Randomization helps balance known and unknown factors between groups, supporting unbiased comparison of treatment strategies.
Why is a hazard ratio often used for survival trials?
A hazard ratio summarizes the relative event rate between groups over the analyzed follow-up period under the assumptions of the statistical model.
8. Limitations
- Registry-level reporting: ClinicalTrials.gov does not report posted statistical analyses for ABC-02.
- Endpoint detail: Additional survival estimates, subgroup analyses, safety summaries, and analysis-population details are not reported in the registry information available here.
- Model assumptions: Time-to-event methods rely on assumptions that should be assessed in a complete statistical analysis plan.
- Follow-up interpretation: Overall survival depends on follow-up duration and subsequent clinical events after randomization.
9. Why This Trial Matters Statistically
| Concept | How it appears in ABC-02 |
|---|---|
| Randomization | Randomized phase 3 treatment comparison |
| Parallel design | Two-arm parallel-group structure |
| Survival analysis | Overall survival as the primary endpoint |
| Censoring | Follow-up ending before death requires time-to-event methods |
| Clinical interpretation | Statistical estimates must be interpreted with their uncertainty |